“…Up until a few years ago, there were no data about the EV serotypes circulating in Europe and causing HFMD, because there is no obligatory notification due to the benign course of infections, as most of them do not require hospitalization. However, the increasing circulation of the emerging types, such as CVA6, firstly detected in an outbreak in Finland during 2008 [ 16 ], along with the detection of more severe cases worldwide, and the appearance of accompanying symptoms, such as onychomadesis [ 15 , 16 , 17 , 18 , 19 , 20 ], suggests the necessity of a surveillance system of HFMD and its clinical evolution in Europe as well [ 21 , 22 , 23 ].…”